Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.
Daniela Kroshinsky, MD, MPH
Advertisement
Daniela Kroshinsky, MD, MPH, works in the Department of Dermatology at the Duke University School of Medicine.
Articles by Daniela Kroshinsky, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
4
Insurance Barriers Tied to Missed Long-Acting PrEP Starts
5